Core Viewpoint - SciSparc Ltd. has signed a definitive agreement to sell its entire ownership interest in MitoCareX Bio Ltd. to N2Off, Inc. for $700,000 and will exchange its remaining shares for common stock in N2Off, representing 40% of N2Off's fully diluted capital stock [1][2]. Group 1: Transaction Details - SciSparc will sell 4,961 shares of MitoCareX to N2Off for $700,000 and exchange the remaining shares for common stock [2]. - The transaction is subject to approval from N2Off's shareholders and will result in MitoCareX becoming a wholly owned subsidiary of N2Off [2]. - Additional N2Off stock will be awarded based on milestone achievements, potentially representing up to 25% of N2Off's fully diluted capital stock [3]. Group 2: Financial Terms - SciSparc and other sellers will collectively receive 30% of N2Off's financing proceeds over five years, capped at $1.6 million [3]. - N2Off has committed to invest $1 million in MitoCareX post-closing [3]. - Dr. Alon Silberman will continue as CEO of MitoCareX under a revised agreement, which includes a restricted stock grant of 5% of N2Off's capital stock, vesting over three years [3]. Group 3: Corporate Governance - Amitay Weiss, chairman of SciSparc's board, also serves as chairman of N2Off's board [4]. - Liat Sidi, a member of SciSparc's board, is also a member of N2Off's board [4]. Group 4: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders [5]. - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder [5].

Core Viewpoint - SciSparc Ltd. has entered into a loan agreement with AutoMax Motors Ltd. for $2 million to support AutoMax's business expansion into the electric vehicle market, following a merger agreement between the two companies [1][3]. Group 1: Loan Agreement Details - The new loan of $2 million will bear an 8% annual interest rate and will be repaid in equal monthly installments of $50,000 plus interest [2]. - AutoMax has the option for early repayment without penalties, and the interest on the loan will be canceled upon the consummation of the merger agreement [2]. - As collateral for the loan, AutoMax has pledged a first-ranking fixed charge on its subsidiary's shares [2]. Group 2: Merger Agreement - In April 2024, SciSparc and AutoMax signed a merger agreement under which SciSparc will acquire 100% of AutoMax, aiming to expand into the automotive sector [3]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies [3]. Group 3: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, including drug development programs for conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder [4]. - The company also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon Marketplace [4].

Core Viewpoint - SciSparc Ltd. has entered into a $2 million loan agreement with AutoMax Motors Ltd. to support AutoMax's business expansion in the electric vehicle sector, following a merger agreement between the two companies [1][3]. Group 1: Loan Agreement Details - The new loan of $2 million will bear an 8% annual interest rate and will be repaid in equal monthly installments of $50,000 plus interest [2]. - AutoMax has the option for early repayment without penalties, and the interest on the loan will be canceled upon the consummation of the merger agreement [2]. - As collateral for the loan, AutoMax has pledged a first-ranking fixed charge on its subsidiary's shares [2]. Group 2: Merger Agreement - In April 2024, SciSparc and AutoMax signed a merger agreement under which SciSparc will acquire 100% of AutoMax, aiming to expand into the automotive sector [3]. - The merger is subject to customary closing conditions, including shareholder approvals from both companies [3]. Group 3: Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, including drug development programs based on cannabinoid pharmaceuticals [4]. - The company is engaged in developing treatments for conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder [4].

Core Viewpoint - N2OFF, Inc. has entered into a definitive agreement to acquire MitoCareX Bio Ltd., a biotech company focused on cancer therapeutics, which will enhance N2OFF's portfolio in sustainable solutions and innovation in agri-tech and clean technology [1][2]. Group 1: Acquisition Details - N2OFF will acquire full ownership of MitoCareX by purchasing 4,961 shares for $700,000 and exchanging additional shares for 40% of N2OFF's fully diluted capital stock [2]. - The Sellers will receive 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years following the acquisition [2]. - The agreement includes milestone-based issuances of up to 25% of N2OFF's common stock, calculated on a fully diluted basis [3]. Group 2: MitoCareX Overview - MitoCareX specializes in developing novel therapies for hard-to-treat cancers by targeting the mitochondrial SLC25 protein family [4]. - The company utilizes advanced 3D comparative modeling and in-vitro screening systems to identify and validate anti-cancer small molecule therapeutics [4]. - The global Cancer Therapeutics and Biotherapeutics market is projected to grow from $194.1 billion in 2024 to $344.1 billion by 2031, indicating significant market potential for MitoCareX's innovations [4]. Group 3: Financial Commitment - N2OFF is committed to financially support MitoCareX's operations with an initial cash investment of $1,000,000 during the first two years post-acquisition [5]. - The board of MitoCareX will be reconstituted with appointees from N2OFF upon closing of the transaction [2][5]. Group 4: Company Background - N2OFF, Inc. focuses on sustainable solutions for energy and agri-tech, including greenhouse gas emissions reduction and solar energy projects [7]. - The company has recently entered the solar PV market and is involved in projects with a total capacity of 111 MWp [7].

Core Viewpoint - SciSparc Ltd. has reached a settlement agreement regarding a lawsuit against six former directors, which includes a cash payment and the termination of a licensing agreement, allowing the company to retain its intellectual property rights [1][2][3]. Group 1: Settlement Agreement - The settlement includes a cash payment of $411,000 from the defendants in exchange for the dismissal of claims against them [2]. - The settlement also terminates a disputed licensing agreement with Dekel Pharmaceuticals Ltd., effective February 5, 2024, allowing SciSparc to retain exclusive global rights to its intellectual property [3]. Group 2: Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders, with drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4]. - The company is also involved in the sale of hemp seed oil-based products through a subsidiary on the Amazon.com Marketplace [4].

Core Insights - SciSparc Ltd. is collaborating with Clearmind Medicine Inc. to develop innovative combination therapies targeting central nervous system disorders and mental health issues [1][3] - A patent application has been published in Mexico for a combination therapy involving MDMA and N-Acylethanolamines, aimed at addressing binge behaviors [2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on cannabinoid pharmaceuticals, with drug development programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [4] - Clearmind Medicine Inc. specializes in psychedelic-derived therapeutics, with a focus on addressing alcohol use disorder and other mental health problems [5] Research and Development - The collaboration has resulted in the filing of 13 patents related to the combination therapies in the U.S. and other jurisdictions [3] - Clearmind's intellectual property portfolio includes 19 patent families and 31 granted patents, indicating a strong focus on research and development in the psychedelic space [5]

Core Points - SciSparc Ltd. has been granted an additional 180-day compliance period by Nasdaq to regain compliance with the minimum bid price rule, extending the deadline to July 14, 2025 [1][3] - The company did not meet the minimum $1.00 bid price requirement during the initial compliance period and has expressed its intention to cure the deficiency, potentially through a reverse share split [2][3] - If the closing bid price reaches at least $1.00 for a minimum of 10 consecutive business days before the deadline, the company will regain compliance [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases [5] - The company is engaged in drug development programs including SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus, utilizing cannabinoid pharmaceuticals [5] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [5]

Core Insights - SciSparc Ltd. has entered into a merger agreement with AutoMax Motors Ltd., a leading automotive importer in Israel, which has received its first shipment of vehicles from JAC Motors, a Chinese automotive company [1][4] - The shipment follows regulatory approvals for direct importation, allowing AutoMax to begin marketing and sales activities for JAC Motors vehicles in Israel [2] - JAC Motors focuses on electric vehicles (EVs), aligning with AutoMax's strategy to meet the rising demand for sustainable transportation solutions in the local market [3] Company and Industry Summary - AutoMax Motors has launched direct import and distribution operations for JAC Motors vehicles, marking a significant milestone in its business [1][2] - JAC Motors is recognized for its innovative range of electric vehicles, supported by advanced R&D and battery technologies, positioning it as a pioneer in sustainable transportation [3] - SciSparc has provided financial support to AutoMax, facilitating the transaction with JAC Motors and potentially paving the way for SciSparc's expansion into the automotive sector through the merger [4]

Core Viewpoint - SciSparc Ltd. is expanding its joint venture MitoCareX Bio Ltd. to include research on pancreatic cancer following positive initial in-vitro results, indicating a significant growth in its therapeutic focus [1][2][3]. Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [6]. Research and Development - MitoCareX has achieved promising results in drug discovery for pancreatic cancer, utilizing a computationally advanced platform that screened millions of small molecules to identify potential anti-cancer treatments [2][3]. - The company is developing a predictive AI model to explore broader chemical spaces, aiming to discover novel anti-cancer compounds targeting the mitochondrial SLC25 protein family [4]. Market Context - Pancreatic cancer is noted as one of the most aggressive cancers, with a 5-year survival rate of only 12% as of 2023, highlighting a significant unmet medical need in this area [5].

On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. CMND, the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, tobacco consumption, shopping, a ...